Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430518 | 0.96 | MAOA (0.44) | MAOAMAOBCYP2A6KDM4EHSD17B10 | |
| SCHEMBL1150797 | 0.88 | KDM4E (0.38) | CYP2A6KDM4EHSD17B10HSD11B1DYRK1A | |
| SCHEMBL18015677 | 0.78 | BCL2L1 (0.41) | MAOAMAOBCYP2A6KDM4EHSD17B10 | |
| SCHEMBL5537592 | 0.78 | MAOA (0.50) | MAOAMAOBCYP2A6FGFR1FGFR2 | |
| SCHEMBL23264525 | 0.76 | CYP2A6 (0.48) | MAOAMAOBCYP2A6FGFR1FGFR2 | |
| SCHEMBL1339705 | 0.76 | DYRK1A (0.50) | MAOAMAOBCYP2A6FGFR1FGFR2 | |
| SCHEMBL19899072 | 0.76 | MAOA (0.48) | MAOAMAOBCYP2A6FGFR1FGFR2 | |
| SCHEMBL2564157 | 0.76 | MAPT (0.52) | MAOAMAOBCYP2A6KDM4EHSD17B10 | |
| SCHEMBL1337967 | 0.76 | CYP2A6 (0.48) | MAOAMAOBCYP2A6HSD17B10FGFR1 | |
| SCHEMBL14632127 | 0.76 | MAOA (0.48) | MAOAMAOBCYP2A6FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4624473-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-4622716-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4479398-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118715215-A | Quinazoline compounds as inhibitors of mutant KRAS proteins and uses thereof | 美国安进公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4384160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024112654-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2000042037-A1 | TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| CN-1207091-A | 1-arylsulphonyl, aryl(thio) carbonyl pyridazino derivatives and methods of preparation | ORTHO PHARMA CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0591582-B1 | Hexahydrobenzo (f) quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0531026-B1 | Hexahydrobenzo[f]quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 1998-11-18 | — | — | EP | disclosed |
| US-5753655-A | PROGESTINS OR ANTIPROGESTINS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997017332-A1 | 1-ARYLSULPHONYL, ARYL(THIO)CARBONYL PYRIDAZINO DERIVATIVES AND METHODS OF PREPARATION | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| EP-0591582-A1 | Hexahydrobenzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5250539-A | 5-alpha reductase inhibitors; administer as therapy for benign prostatic hyperplasia, hirsutism and acne | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0531026-A1 | Hexahydrobenzo[f]quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | MAOA 4647/4885MAOB 4559/4885CYP2A6 3843/4885 |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MAOA 4235/4885MAOB 3391/4885CYP2A6 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.